Showing 2531-2540 of 2735 results for "".
- Cutera Launches truSculpt iD, Personalized Body Sculptinghttps://modernaesthetics.com/news/cutera-launches-trusculpt-id-personalized-body-sculpting/2472065/Cutera, Inc. introduced truSculpt® iD, which the company describes as the next evolution in body sculpting with unique hands-free capability and the ability to treat a full abdomen in as little as 15 minutes. truSculpt® iD’s sleek design and comprehensive handpiece options give phys
- RealSelf: Laser & Energy Report Identifies Key Trendshttps://modernaesthetics.com/news/realself-laser-energy-report-identifies-key-trends/2472067/Demand for fat reduction is at an all-time high, and interest in vaginal rejuvenation continues to surge. These are among key findings of the newly release RealSelf US Laser & Energy Report, released this week. First in a ne
- TempSure Vitalia from Cynosure Hits North American Markethttps://modernaesthetics.com/news/tempsure-vitalia-from-cynosure-hits-north-american-market/2472068/Hologic's Cynosure division has launched TempSure™ Vitalia in North America. TempSure Vitalia is an FDA-cleared and Health Canada-approved advanced radiofrequency treatment that delivers therapeutic heat to inter
- InMode Launches Triton Multi-Wavelength Hair Removal Laserhttps://modernaesthetics.com/news/inmode-launches-triton-multi-wavelength-hair-removal-laser/2472069/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- Alana Sine Appointed Chief Financial Officer at Merz North Americahttps://modernaesthetics.com/news/alana-sine-appointed-chief-financial-officer-at-merz-north-america/2472072/Merz North America has appointed Alana Sine to Chief Financial Officer (CFO), Merz North America. Ms. Sine has served as interim CFO since March 2018. Ms. Sine will lead the finance function for North America, overseeing financial report
- Modern Aesthetics® Announces New Tweet Chat Series -- #RealDealAestheticshttps://modernaesthetics.com/news/modern-aesthetics-announces-new-tweet-chat-series-realdealaesthetics/2472073/Modern Aesthetics® magazine is launching a new Tweet chat series -- #RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The first Tweet chat focuses on filler selection in a r
- ARTAS Training Available: Restoration Robotics Launches Continuing Education Serieshttps://modernaesthetics.com/news/artas-training-available-restoration-robotics-launches-continuing-education-series/2472080/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- Revance Vet Tapped as New Evolus CFOhttps://modernaesthetics.com/news/revance-vet-tapped-as-new-evolus-cfo/2472086/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Restylane Lyft Now FDA-Approved for Handshttps://modernaesthetics.com/news/restylane-lyft-now-fda-approved-for-hands/2472088/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older then 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- FDA Says No to Evolus' Botox Rivalhttps://modernaesthetics.com/news/fda-says-no-to-evolus-botox-rival/2472089/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more